Objective. To assess the impact of investment in national tuberculosis programs (NTPs) on NTP performance and tuberculosis burden in 22 high-burden countries, as determined by the World Health Organization (WHO).
Tuberculosis mainly affects economically and socially vulnerable individuals in low-income and middleincome countries [1] . In 2009, there were an estimated 9.4 million incident cases of, 14 million prevalent cases of, and 1.7 million deaths due to tuberculosis globally [2] .
Tuberculosis control is crucial in achieving the Millennium Development Goals (MDGs) [1, 3] .
International targets for implementation are to detect 70% of sputum smear-positive cases and to cure 85% of those detected; targets for impact (which are linked to MDG target 6) are to ensure that the tuberculosis incidence is falling by 2015 and that tuberculosis prevalence and mortality are halved by 2015, compared with levels in 1990 [4] . Global commitment to achieve MDG target 6 has spurred increased international financing of activities to tackle human immunodeficiency virus (HIV) infection, tuberculosis, and malaria, especially since the creation of The Global Fund to Fight AIDS, Tuberculosis, and Malaria (hereafter, the ''Global Fund'') in 2002. By the end of 2010, the Global Fund had approved $21.7 billion and disbursed $13 billion, of which $3.6 billion has been approved and $2 billion disbursed for tuberculosis control [5] . Total funding for tuberculosis control from both domestic and external sources is expected to reach nearly $5 billion in 2011 [2] , with the Global Fund projected to provide .80% of the external funding in low-income and middle-income countries the same year [5] . In the 22 highest tuberculosis burden countries, total funding available for tuberculosis control has markedly increased since 2002 and was expected to reach $3 billion [2] .
While investment in tuberculosis control has increased substantially, the effect of increased investments in national tuberculosis programs (NTPs) on their performance and, ultimately, their impact on tuberculosis burden (ie, incidence, prevalence, and mortality) has not been estimated. Dye and colleagues [6] used data from 134 countries from 1997 to 2006 to examine the relationship between NTP performance and trends in tuberculosis incidence. They found limited evidence that NTP performance is the principal determinant of tuberculosis incidence trends, concluding that although tuberculosis control programs have averted millions of deaths, their expected impact on incidence may only become detectable in the longer term. We built upon this study by assessing the relationship between investments in NTPs, indicators of NTP performance, and tuberculosis burden for the 22 countries with the highest tuberculosis burden, as determined by the World Health Organization over the period 2002-09.
METHODS
The following 22 high-burden countries collectively account for about 80% of the world's tuberculosis cases: Afghanistan, Bangladesh, Brazil, Cambodia, China, Democratic Republic of the Congo (DR Congo), Ethiopia, India, Indonesia, Kenya, Mozambique, Myanmar, Nigeria, Pakistan, the Philippines, Russian Federation (Russia), South Africa, Thailand, Uganda, the United Republic of Tanzania (Tanzania), Vietnam, and Zimbabwe [2] . These high-burden countries have made focused efforts and received support to obtain high-quality and complete data on tuberculosis epidemiology, financing, and health service delivery. Although tuberculosis services in developed countries have high-quality data, these countries have a low burden of tuberculosis and are not the focus of this study. Data used in our analysis and their sources are summarized in Table 1 .
We used WHO data on tuberculosis incidence (all forms of tuberculosis), prevalence (all forms), and mortality (excluding HIV-positive persons); all values were expressed cases per 100 000 population in a given year [2] . These estimates are reviewed and updated in regional and country workshops, using a framework and associated tools developed by the WHO Global Task Force on TB Impact Measurement [2] . We used WHO data sources for NTP expenditures [6, 7] in each country, which include both domestic and external financing sources. For additional updated information on external financing, we used Organization for Economic Cooperation and Development (OECD) Development Assistance Committee (DAC) data on Official Development Assistance (ODA) to ascertain gross disbursements between 2002 and 2009 for tuberculosis control from bilateral and multilateral donors and to compute both the total disbursements and Global Fund share of contributions [8] (Table  2) . ODA data for one of the countries, Russia, were not available because the country is a member of the Group of 8 forum and so is not included in the DAC List of ODA Recipients [9] .
Estimates of the burden of disease caused by tuberculosis (measured in terms of incidence, prevalence, and mortality) are produced annually by the WHO, using information gathered through surveillance systems (case notifications and death registrations), special studies (including surveys of the prevalence of disease and in-depth analysis of surveillance data), expert opinion, and consultations with countries [2] . Incidence is defined as the number of new and relapse cases of tuberculosis (all forms) occurring in a given year. Prevalence is defined as the number of cases of tuberculosis (all forms) at a given point in time (ie, the middle of the calendar year). Mortality is defined as the number of deaths caused by tuberculosis, excluding deaths occurring in HIV-positive individuals, according to the definitions used in the International Classification of Diseases, Tenth Revision (ICD-10). Full details of methods for estimating the global burden of tuberculosis are described elsewhere [2] . Case detection and treatment success rates have been the main measures of progress in NTP performance [10] and estimated by WHO [2] . The case detection rate is calculated as the number of notified cases of tuberculosis in 1 year divided by the estimated number of incident cases of tuberculosis in the same year and is expressed as percentage [2] . The case detection rate is difficult to estimate because of the limited accuracy of both the numerator (the number of new cases of tuberculosis notified in a country in a year) and the denominator (the estimated national incidence of tuberculosis) [11] . We chose to create a dummy variable for case detection rate because an estimate of the incidence is used in computing the case detection rate, which may bias the model. The treatment success rate is defined as the percentage of patients who are cured and complete treatment. We used the treatment success rate for new pulmonary smear-positive (and/or culture-positive) cases.
We used the 70% case detection rate (the STOP TB Partnership target to detect 70% of sputum smear-positive cases) as the threshold value and examined whether achieving it significantly affects the tuberculosis burden. We also created a dummy variable for treatment success rate and used a treatment success rate of 85% as the threshold value (the Stop TB Partnership target cure rate for the sputum smearpositive tuberculosis cases detected). We chose to create dummy variables for case detection and treatment success rates because the key question we wanted to address was whether reaching the international targets for implementation (ie, detection of 70% of sputum smear-positive cases and cure of 85% of those detected) had an impact on tuberculosis burden. Use of dummy variables for these 2 rates makes the results more interpretable than examining how a percentage increase in these rates affects the tuberculosis burden. Moreover, since the case detection rate is calculated from the estimated incidence, use of the dummy variable minimizes bias in the model. In our regression models, we used absolute values of case detection and treatment success rates, which gave similar final results (data are not shown but are available on request). As a measure of overall economic development, we used purchasing power parity (PPP)-converted gross domestic product (GDP) at 2005 constant prices from the World Penn Table [12] and population-structure data (proportion of population aged 0-14 years) from the World Bank's World Development Indicator database [13] . One country, Myanmar, lacked data for gross domestic product (GDP) per capita. We used adult HIV prevalence data from the Joint United Nations Program on HIV/AIDS [14] . Five countries (Afghanistan, Brazil, China, DR Congo, and Ethiopia) lacked annual HIV prevalence data.
First, to estimate the overall time trends in tuberculosis burden in the 22 countries and by region over 2002-2009, we performed fixed-effects model regression analysis with tuberculosis with tuberculosis disease incidence, disease prevalence or mortality as the dependent variable and year as an independent variable.
Second, to examine whether increased NTP expenditure was associated with better performance of NTP indicators, as measured by case detection rate and treatment success rate, we plotted the NTP expenditure per capita (general population) and each of these rates. We also performed fixed-effects model analysis with either case detection rate or treatment success rate in the following year, as the dependent variable and estimated whether the increase in NTP expenditure was associated with an increase in these rates.
Finally, to estimate the effects of NTP performance on tuberculosis burden, we conducted panel data analysis using the model expressed in the equation below. Panel data analysis enabled analysis of the relationship between NTP performance and tuberculosis burden while controlling for between-subject variability, resulting in more-efficient estimators of treatmentrelated effects (eg, changes in case detection rate), compared with corresponding cross-sectional designs.
The tuberculosis burden in country i during year t is represented by Y. Y is measured either by incidence, prevalence, or mortality rate and is given in cases per 100 000 population. We used a dummy variable for tuberculosis case detection rate, which is denoted by CDR; it is equal to 1 when the rate is .70% and is equal to 0 otherwise. As discussed, we chose to do this because the case detection rate is calculated using the number of incident cases, and therefore correlation could bias the result. The treatment success rate is denoted by TSR; it is equal to 1 when the rate is .85% and equal to 0 otherwise. The GDP per capita (PPP) is denoted by GDP, and the percentage of young individuals (%, 0-14 years) in the population is denoted by Pop. The HIV prevalence is denoted by HIV; in models in which the HIV prevalence is not included, b 5 is equal to 0. Country and year fixed effects are included in fixed-effects models.
A wide range of behavioral and biological risk factors such as smoking and diabetes affect the tuberculosis burden [6] . However, annual data on risk factors other than HIV infection for these countries at the population level were either limited or nonexistent and thus were not included in the model. The model therefore focused on addressing what factors were important in driving down the tuberculosis burden rather than on identifying all possible determinants. Moreover, as an additional indicator of general health services and inequity, we initially included the percentage of private health expenditures that were out of pocket, as specified in the World Development Indicator database, but we excluded these data in the final analysis because they were insignificant in all models and decreased the sample size.
We started with pooled ordinary least squares (OLS) analysis and then used fixed-effects modeling. Because the country fixed effects were jointly significant in every regression analysis, we chose to include fixed effects in our models. By using a fixed-effects model, we were able to control for such omitted variables and to control for bias that may be country specific but constant over time. We then conducted the Wooldridge test for autocorrelation in panel data, as well as a test for heteroskedasticity, and all 3 dependent variables indicated the presence of both autocorrelation and heteroskedasticity [15] . We therefore ran models with feasible generalized least squares (FGLS) analysis and corrected for autocorrelation and heteroskedasticity.
RESULTS
We found that, across 21 of 22 high-burden countries (Russia is not included in the DAC list as an ODA recipient), total ODA disbursement during 2002-2009 for tuberculosis control was $1.1 billion, of which the Global Fund share comprised 64% ( Table 2 , columns 1 and 2). This excludes Global Fund contributions to tuberculosis control through HIV grants; for example, the ODA data show no Global Fund contribution to tuberculosis control in South Africa, but tuberculosis programs in the country also receive financing from Global Fund financed HIV grants. The total amount of the NTP budget in the 22 countries during 2002-2009, which includes domestic funding by the government in addition to external funding (loans and grants), was .$10 billion [16] . When we pooled the 22 countries, the average estimated incidence, prevalence, and mortality rates in 2009 were 302, 431, and 37 cases per 100 000 population, respectively (Table 2, columns 3-5). The burden measurements varied within the 22 countries: the incidence ranged from 96 cases per 100 000 population in Brazil to 971 cases per 100 000 population in South Africa, and mortality ranged from 2.1 cases per 100 000 population in Brazil to 76 cases per 100 000 population in DR Congo.
Between 2002 and 2009, incidence, prevalence, and mortality declined annually by 2.86, 9.84, and 1.90 cases per 100 000 population, respectively (Table 3) . Analysis of regional time trends of these indicators revealed that the annual decline in incidence was greater in high-burden countries in Africa than in those in Asia (5.32 vs 1.28 cases per 100 000 population). In contrast, the annual declines in prevalence and mortality in high-burden countries were greater in Asia than in Africa (prevalence, 13.10 vs 7.84 cases per 100 000 population; mortality, 2.51 vs 1.53 cases per 100 000 population).
Evaluation of the association between NTP expenditure and NTP performance, as measured by case detection rate and treatment success rate, revealed that higher NTP expenditure per capita correlated with higher case detection rate the following year ( Figure 1A) . Elimination of outliers (by excluding Russia and South Africa, which have large NTP expenditures per capita) showed a stronger association ( Figure 1B) . In contrast, treatment success rate had a pattern distinctively different from that of case detection rate, in which the increase in NTP expenditure per capita did not appear to be associated with higher treatment success rate ( Figure 1C) , even when excluding Russia and South Africa ( Figure 1D) .
The results of the fixed-effects regression analysis with dependent variables as the NTP performance indicator and with NTP expenditure per capita as the explanatory variable, as shown in Figure 1A and 1B, suggests that higher per capita NTP expenditure was associated with higher case detection rate. A $1 increase in NTP expenditure (including domestic and external sources) per capita was significantly (P , .05) associated with a 1.9% (95% confidence interval [CI], .12%-3.6%) higher case detection rate the subsequent year for the 22 high-burden countries between 2002 and 2009. The results of regression analysis for 20 countries (Russia and South Africa were excluded) indicated that a $1 increase in NTP expenditure per capita was significantly (P , .001) associated with a 37.6% (95% CI, 19.9-55.4) higher case detection rate ( Figure 1B) . There was no association between NTP expenditure per capita and treatment success rate ( Figure 1C and 1D) . Further details of the results are available on request.
The results of multivariate regression analysis of tuberculosis burden and factors that influence the burden are shown in Tables 4-6, respectively, for incidence, prevalence, and mortality. For each table, column 1 shows the pooled OLS results, columns 2 and 3 show the fixed-effects regression results, and columns 4 and 5 show the FGLS results, correcting for autocorrelation and heteroskedasticity. Columns 3 and 5 show models that included HIV prevalence. Columns 4 and 5, which indicate whether the country reached a case detection rate of .70%, show that this factor was significantly associated with tuberculosis burden in all models. During the subsequent year, countries reaching a case detection rate of .70% experienced declines of 36.4 incident cases per 100 000 population (Table 4) , 116.0 prevalent cases per 100 000 population (Table 5) , and 7.2 deaths per 100 000 population (Table 6 ). When we included HIV prevalence in the models these associations were even stronger: the 17 countries for which HIV trend data were available showed that when a country reaches the 70% case detection rate had an average 88.1/100 000 lower incidence rate (Table 4) , a 183.6/100 000 lower prevalence rate (Table 5) , and a 11.9/100 000 lower mortality rate the subsequent year (Table 6) .
A higher GDP per capita was significantly associated with reductions in tuberculosis incidence (P , .01; Table 4 , column 4) and mortality (P , .01; Table 6 , column 5) but not prevalence (Table 5 , column 5). A higher prevalence of HIV infection was associated with a higher tuberculosis incidence (Table 4 , column 5) and prevalence (Table 5 , column 5) and a lower mortality, excluding HIV prevalence (Table 6 , column 5). The proportion of the population that was younger was significantly associated with higher tuberculosis prevalence (P , .01; Table 5 , column 4) and mortality (P , .05; Table 6 , columns 4 and 5). Reaching a treatment success rate of .85% was not significant in any of the final models, even though involved fixed-effects analysis (Table 4 , column 2; Table 5, columns 2  and 3; and Table 6 , columns 2 and 3).
DISCUSSION
In the 22 high-burden countries, increase in funding for NTP since 2002 and improvement in case detection and treatment Coefficients are per annum change in the number incident cases, prevalent cases, or deaths per 100 000 population (standard errors) and were calculated using fixed-effects models. a P , .01.
success rates were significantly associated with a downward trend in the tuberculosis burden. A $1 increase per capita in the NTP budget (including domestic and external sources) was associated with a 1.9% annual increase in estimated overall case detection rate the following year for these countries between 2002 and 2009. In the final models, achieving high case detection rate (ie, .70%) was associated with significantly (P , .01) lower tuberculosis incidence, prevalence, and mortality the following year, even when controlling for general economic development and HIV prevalence as risk factors. Dye et al [6] assessed the impact of different measures of tuberculosis-control intensity (expenditure on tuberculosis control, new cases of tuberculosis detected, and cases of treatment success) on tuberculosis burden. By using data from 134 countries from 1997 to 2006, they found that, more than a decade after the internationally recommended tuberculosis control strategy was first implemented, only 1 direct measure of tuberculosis control intensity in a single region (Latin America) was associated with decreasing tuberculosis incidence. None of these direct measures of NTP performance were associated with tuberculosis trends globally, and they concluded that tuberculosis diagnosis and treatment programs had not yet become the principal determinants of tuberculosis transmission and incidence trends, even though they may do so in the future.
We used recent data up to 2009 and limited the analysis to the 22 high-burden countries. This may have helped show the significant correlation between tuberculosis program intensity and tuberculosis burden, owing to higher quality data and a time frame that coincided with scaled up investment. Another study [17] also suggested that changes in estimated national tuberculosis incidence are more strongly associated with changes in national socioeconomic indices and the general health status of the population than with NTP performance. Our finding was consistent with findings of Oxlade et al [17] with respect to the association between an increase in GDP per capita and reductions in tuberculosis incidence and mortality rates. GDP per capita actually had a negative impact on tuberculosis prevalence, when HIV prevalence was included in the model. This may be due to the high correlation between proportion of younger individuals in the population and GDP per capita (correlation coefficient, .0.7). The relationship between the increase in GDP per capita and prevalence may also be due to increases in wealth inequality in countries experiencing economic growth [18] , when the tuberculosis program performance is already taken into account in the model. For example, in European countries, wealth inequality (measured by public wealth index) and tuberculosis burden appear to be inversely correlated [19] . The positive impact of increased GDP per capita on the tuberculosis burden through, for example, improved access to health facilities and improved availability of treatment may be mitigated by the negative impact of factors such as the acceleration of income inequality and intensification of the tuberculosis burden among the vulnerable populations in the society.
Incidence has been the most commonly used indicator for measuring tuberculosis burden. Improved case detection and treatment success rates reduce tuberculosis mortality by reducing the average duration of infectiousness and the transmission levels [20] . Tuberculosis mortality declines more rapidly than tuberculosis incidence because drug treatment reduces not only transmission but also the case-fatality rate. Tuberculosis incidence can remain stable or even increase when case detection and treatment success rates are rising, if the risk of developing tuberculosis at the population level is increasing [20] . Therefore, incidence may not be the most responsive indicator for measuring short-term changes in the tuberculosis burden attributable to changes in health service performance, including that of tuberculosis control programs. Hence, in our analysis we chose to examine changes in tuberculosis prevalence and mortality rates in addition to incidence, in contrast to earlier studies that focused exclusively on incidence [6, 17] . In the fixed-effects models, the prevalence and mortality rates were more sensitive than the incidence rate to changes in NTP performance indicators. In addition to indicators of NTP performance, we included GDP per capita, population structure, and HIV prevalence as the main tuberculosis risk factors that could affect tuberculosis burden. We chose these variables on the basis of earlier studies, such as those by Dye et al [6] and Oxlade et al [17] , which identified development, economy, population, behavioral and biological risk factors, health services, and tuberculosis control as affecting the national trends in tuberculosis burden. A wide range of factors affects tuberculosis risk. We assumed that behavioral and biological risk factors, such as malnourishment and access to improved water sources, could be proxied by income per capita. Annual population-level data on other risk factors, such as diabetes and smoking, for these countries were limited or nonexistent. The sample size of the regression models would have been substantially reduced if we chose to include these variables. Diabetes and smoking have likely increased over the last decade in these countries (http://www. who.int/research/en/), so our model may underestimate the impact of improved tuberculosis control programs and increased NTP funding. Our use of fixed-effects modeling takes care of any risk factors that are specific to countries and do not change over time. Tuberculosis incidence can remain stable or even increase when case detection and treatment success rates are improving, if the risk of developing tuberculosis at the population level is increasing.
For these 22 countries, we used the most-complete and highest-quality tuberculosis data (covering epidemiology, financing, and health service delivery) that are available. Estimates are thoroughly reviewed and updated in regional and country workshops, using frameworks and associated tools developed by the WHO Global Task Force on Tuberculosis Impact Measurement [2] . We do, however, acknowledge data limitations. The analysis revealed the presence of autocorrelation and heteroskedasticity. There are many potential sources of uncertainty associated with estimates of tuberculosis incidence, prevalence, and mortality, as well as measurement of case detection and treatment success rates. Notification data are of uneven quality. Cases may be underreported, misclassified, or over-reported. Mortality estimates incorporated sources of uncertainty, such as sampling uncertainty in the underlying measurements of tuberculosis mortality from data sources and uncertainty in estimates of incidence [2] . In the data we used, tuberculosis mortality is defined as the number of deaths caused by tuberculosis, excluding those in HIV-positive individuals, using definitions from the ICD-10 [16] . Although tuberculosis mortality is best measured directly by use of vital registration data, none of the 22 high-burden countries were among the countries assessed to have highquality data (as defined by codes that are .90% complete, with ,10% considered to be ill defined). Three countries (Brazil, the Philippines, and Russia) were among the countries considered to have data of medium quality, and 2 countries (South Africa and Thailand) were considered to have death registration data of low quality [16] . The statistical methods addressed the weakness of the data to the best extent possible and still found a robust and significant association between improved NTP performance and reduced tuberculosis burden. For better modeling of tuberculosis burden and its explanatory variables, we also conducted 2-stage least squares regression analysis because NTP budget (input) should affect the tuberculosis burden through its output (eg, case detection and treatment success rates). Nonetheless, NTP budget appeared to be a poor instrumental variable, resulting in poor correlation in the first stage analysis (data are not shown but are available on request).
The total funding available for tuberculosis control in the 22 high-burden countries has increased since 2002 and is expected to reach $3.0 billion in 2011 [2] . Our results suggest that increased investment in NTPs, accompanied by improved case detection rates, will help further reduce the global burden of tuberculosis. An increased and sustained funder, donor, and governmental commitment to ensuring high-quality national Tuberculosis programs is required. 
